KDR and cancer: Amongst its cancer-related molecular interactions, Gal-3 has been shown to be a ligand for the RTKs epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor-2 (VEGFR-2), activating signalling pathways for cell proliferation and angiogenesis respectively [13].